Delta Sleep-Inducing Peptide

DSIP (Delta Sleep-Inducing Peptide) is a nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) originally isolated from rabbit cerebral venous blood during electrically-induced sleep by Schoenenberger and Monnier (1977). Despite its name, DSIP doesn't simply "induce" sleep — it modulates sleep architecture, increasing the ratio of slow-wave (delta) sleep to total sleep time, improving sleep efficiency without sedation. It also shows stress-protective effects: reducing cortisol reactivity, normalizing disrupted circadian patterns, and acting as an adaptogen in the hypothalamic-pituitary-adrenal (HPA) axis. Clinical trials (primarily European, 1980s-1990s) demonstrated improvements in chronic insomnia, narcolepsy-associated sleep disruption, and withdrawal-related sleep disturbance. In TRT/peptide contexts, DSIP is used to improve sleep quality — which is critical because GH is primarily released during slow-wave sleep, and poor sleep blunts the endogenous GH response to secretagogue therapy. The mechanism is not fully elucidated; DSIP appears to modulate multiple neurotransmitter systems (GABAergic, serotonergic, glutamatergic) and has opioid-modulatory properties without binding opioid receptors directly. Research interest has revived in the 2020s due to the peptide therapy movement.